📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.
Rohto Pharmaceutical Co Ltd
Rohto Pharmaceutical's GHG Emissions Data Preview
In 2024, Rohto Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Rohto Pharmaceutical has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
Location-Based | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  b | Copy restricted. Please purchase to unlock this data.  b | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | 0000000 |
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
a
b
a
a
bVerified Sources Behind Rohto Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Rohto Pharmaceutical’s data sources below and access millions more through our Disclosure Search.
Insights into Rohto Pharmaceutical's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions ofRohto Pharmaceutical amounted to10,222metric tons of CO2 equivalent.This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Rohto Pharmaceuticaldecreased by 19.65%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
Rohto Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Rohto Pharmaceutical's Scope 1 emissions?
In 2024, the total Scope 1 emissions of Rohto Pharmaceutical were 6,900 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Has Rohto Pharmaceutical reduced its Scope 1 emissions over time?
Since 2019, Rohto Pharmaceutical's Scope 1 emissions have increased by 45.6%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year(2023), Rohto Pharmaceutical's Scope 1 emissions decreased by 9.37%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
What are Rohto Pharmaceutical's Scope 2 emissions?
In 2024, Rohto Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 3,322 tCOâ‚‚e using the market-based method.a
Has Rohto Pharmaceutical reduced its Scope 2 emissions over time?
Since 2019, Rohto Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Market-Based)have decreased by 63.96%, reflecting a declining long-term trend in Scope 2 emissions over time.ab
Compared to the previous year(2023), Rohto Pharmaceutical's Scope 2 emissions(Market-Based) fell by 34.98% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
What methodology does Rohto Pharmaceutical use for Scope 2 reporting?
In 2024, Rohto Pharmaceutical reported its Scope 2 emissions using the market-based method.a
Rohto Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
Insights into Rohto Pharmaceutical's Value Chain Emissions
In 2024, Rohto Pharmaceutical reported 229,563 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Rohto Pharmaceutical includes a breakdown across 11of the 15 Scope 3 categories defined by the GHG Protocol,matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
Rohto Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Rohto Pharmaceutical's Scope 3 emissions?
In 2024, Rohto Pharmaceutical reported total Scope 3 emissions of 229,563 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).a
Approximately 97.47%of these emissions originated from upstream activities such as purchased goods and capital goods, while 2.53%came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Rohto Pharmaceutical's Scope 3 emissions remained relatively stable, indicating that Rohto Pharmaceutical's emissions have plateaued with no significant change in its value chain footprint.ab
What categories of Scope 3 emissions does Rohto Pharmaceutical disclose?
In 2024, Rohto Pharmaceutical reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of Rohto Pharmaceutical's Scope 3 emissions?
In 2024, the largest contributors to Rohto Pharmaceutical's Scope 3 emissions were:a
- Purchased Goods and Services (Cat. 1): 196,544 tCOâ‚‚e(85.62%)
- Capital Goods (Cat. 2): 13,865 tCOâ‚‚e(6.04%)
- Upstream Transportation and Distribution (Cat. 4): 5,096 tCOâ‚‚e(2.22%)
Rohto Pharmaceutical's Scope 3 Emissions by Categories
Insights into Rohto Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers
In 2024, Rohto Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 6,900 tCOâ‚‚e and total revenues of USD 1,788 millions. This translates into an emissions intensity of 3.86 tCOâ‚‚e per millions USD.a
Rohto Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers
How does Rohto Pharmaceutical's GHG emissions intensity compare to its peers?
In 2024, Rohto Pharmaceutical reported a Scope 1 emissions intensity of 3.86 tCOâ‚‚e per millions USD. Compared to the peer group median of 14.12, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
Where does Rohto Pharmaceutical rank on GHG emissions intensity within its industry?
In 2024, Rohto Pharmaceutical ranked 5 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCOâ‚‚e per millions USD).a
This places Rohto Pharmaceutical among the top performers, with one of the lowest emissions intensities relative to peers.a
Insights into Rohto Pharmaceutical's Total Carbon Footprint
In 2024, Rohto Pharmaceutical reported a total carbon footprint of 239,785 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 0.19% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.ab
The largest contributor to Rohto Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 95.74% of the company's total carbon footprint, followed by Scope 1 emissions at 2.88%.a